MedTrace Logo

Study of a Live rNDV Based Vaccine Against COVID-19

NCT04871737 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2023-07-25

No results posted yet for this study

Summary

This is a Phase 1, open-label, non-randomized, dose-escalation study using three doses and two schemes of administration of a recombinant vaccine against SARS-CoV-2 based on a viral vector (Newcastle Disease virus) in 90 healthy volunteers at a single research site in Mexico City.

Conditions

Interventions

BIOLOGICAL

Recombinant NDV Vectored Vaccine for SARS-CoV-2

Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Sponsors & Collaborators

  • National Council of Science and Technology, Mexico

    collaborator OTHER

  • Agencia Mexicana de Cooperación Internacional para el Desarrollo. AMEXCID

    collaborator UNKNOWN

  • Laboratorio Avi-Mex, S.A. de C.V.

    lead INDUSTRY

Principal Investigators

  • Samuel Ponce de Leon, MD · Universidad Nacional Autonoma de Mexico

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-05-20
Primary Completion
2022-08-21
Completion
2022-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04871737 on ClinicalTrials.gov